Novartis forged a licensing agreement with Arrowhead Pharmaceuticals to develop ARO-SNCA, an RNA interference-based therapy targeting alpha-synuclein implicated in Parkinson's disease. The deal, worth over $2.2 billion including milestones and royalties, leverages Arrowhead's TRiM platform for efficient CNS delivery. Novartis aims to develop additional targets using this platform. The collaboration represents a renewed effort to address neurodegenerative diseases through RNA-based therapeutics.